SCHEMBL275205

SCHEMBL275205

CC(C)(C)OC(=O)N1CCC(Oc2ccc(I)cc2C=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.52
PDE4D Q08499 3/20 0.52
PDE4A P27815 2/20 0.52
PDE4C Q08493 2/20 0.52
GPR119 Q8TDV5 9/20 0.51
KDM1A O60341 1/20 0.46
TOP2A P11388 1/20 0.46
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
HRH3 Q9Y5N1 1/20 0.42
CHEK2 O96017 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278899 0.94 PDE4B (0.49) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL2420719 0.87 PDE4B (0.52) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL274655 0.87 PDE4B (0.52) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL275404 0.85 GPR119 (0.52) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL275604 0.84 PDE4B (0.43) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL279159 0.84 PDE4B (0.43) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL275719 0.84 CHEK2 (0.44) GPR119CHEK2
SCHEMBL1889385 0.84 KDM1A (0.54) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL16280397 0.82 PDE4B (0.51) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL279337 0.82 PDE4B (0.44) PDE4BPDE4DPDE4APDE4CGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT PDE4B 3594/4885PDE4D 2759/4885PDE4A 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.